ISO 639-1
To summarize evidence on the cost-effectiveness of PD-(L)1 inhibitors as first-line therapy in patients with high PD-L1 expression non-small cell lung cancer. Methods: A…
Read more →This economic evaluation compares two treatment strategies for patients with a diabetic foot ulcer (DFU): a lipido-colloid technology with nano-oligosaccharide factor (TLC-NOSF) dressing versus…
Read more →Endometriosis-related dysmenorrhea and pelvic pain impose significant economic and quality-of-life burdens. This study evaluated the cost-effectiveness of dienogest compared to gonadotropin-releasing hormone agonists (GnRH-a)…
Read more →To analyze the cost-utility of regorafenib as a second-line treatment for patients with hepatocellular carcinoma who had progressed on sorafenib in Vietnam from a…
Read more →This study aimed to assess the cost-utility of luseogliflozin compared with Standard of Care (SoC) for patients with T2DM in Vietnam, under two reimbursement…
Read more →